Eczacıbaşı Momentum
VC Fund
Eczacıbaşı Momentum is a VC fund focused on E-Commerce and Information Technology. Eczacıbaşı Momentum invested in three venture companies and a venture capital fund; Their goal is to invest US$30 million over the next five years as they continue to partner with funds and startups that shape the new normal of modern life, focusing on well-being, consumption, and home-living.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 40%
- Fund size:
- $30M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Eczacıbaşı Momentum invests in
Stages Eczacıbaşı Momentum invests in
Countries Eczacıbaşı Momentum invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $125k–$9M
- Pre-Seed
- $125k–$125k
- Series A
- $2.5M–$65M
Investment Focus
Industry
- E-Commerce 3 (20%)
- Information Technology 3 (20%)
- FinTech 2 (13%)
- Software 2 (13%)
- Health Care 2 (13%)
Stage
- Seed 5 (33%)
- Series A 5 (33%)
- Pre-Seed 1 (7%)
- Series D 1 (7%)
- Funding Round 1 (7%)
Country
- Turkey 5 (33%)
- United States 4 (27%)
- Spain 1 (7%)
- Morocco 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Berktug Incekas
Head of VC Investments
|
Head of VC Investments | Total investments: 5 | Find email | |
Çağdaş Aygün
VC Investments
|
VC Investments | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BillionToOne
|
BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries.BillionToOne was founded in 2016 and is headquartered in Menlo Park, California. | $130M / Series D / Jun 21, 2024 | |
Chari
|
Chari is an e-commerce and fintech app for traditional retailers in French-Speaking Africa allowing them to order any consumer goods they sell and get delivered for free in less than 24 hours. Chari is also a financial services provider for these retailers, offering them microloans | Venture - Series Unknown / Apr 19, 2024 | |
Ecomercek
|
Ecomercek evaluates and scores the environmental and health effects of cosmetics, skin care, personal hygiene, and home care products. They provide content consultation before products are released. They work with businesses to raise consumer awareness through a variety of specialties. | $125K / Pre-Seed / Oct 23, 2023 | |
Flora
|
We are a Bay Area-based sustainable e-commerce marketplace. We acquiring, nurture and grow e-commerce brands on a mission to make quality, sustainable products more accessible and affordable. Flora exists to empower people to live sustainably in their daily lives because we believe that inspiring small sustainable choices can lead to a big impact. | $9M / Seed / Sep 28, 2022 | |
|
Ecomercek
|
Ecomercek evaluates and scores the environmental and health effects of cosmetics, skin care, personal hygiene, and home care products. They provide content consultation before products are released. They work with businesses to raise consumer awareness through a variety of specialties. | $125K / Seed / May 06, 2022 | |
|
Ecomercek
|
Ecomercek evaluates and scores the environmental and health effects of cosmetics, skin care, personal hygiene, and home care products. They provide content consultation before products are released. They work with businesses to raise consumer awareness through a variety of specialties. | $125K / Pre-Seed / May 06, 2022 | |
RS Research
|
RS Research is a next generation therapeutics company developing novel nanomedicines. We have developed a pioneering class of nanocarriers with which we currently have proprietary programs in various stages of preclinical development for treatment of cancer.Our nanocarrier platform is highly tunable with a plug & play approach, allowingspeedy development of targeted nanomedicines with superior performance.Along with moving our very own candidates toward clinic, we provide preclinical services to industrial and academic partners. We have specific expertise in biosimilar characterization as well as in vivo experiment design. | $12M / Series A / Dec 15, 2021 | |
Newlab
|
Newlab is a singular community of experts and innovators applying transformative technology to solve the world's biggest challenges. t brings together entrepreneurs, engineers, and inventors from various industries to work on cutting-edge technologies and projects. Newlab focuses on fostering collaboration and providing resources to supportthe development of innovative solutions. Newlab membership and studios bring together entrepreneurs, engineers, inventors, and industry leaders to create sustainable solutions and enterprises. Newlab employs technologies including robotics, AI, and material science to transform what matters most—health, environment, media, cities, and infrastructure. | $12.4M / Nov 19, 2021 | |
Virasoft
|
ViraSoft’s ambition is to be the first choice in the field of digital pathology in Turkey and in mid-term enabling to give service to the neighboring countries. Together with the R&D activities, we aim to improve the efficiency and effectivity in the pathology process and reach significant diagnosis results. | $2.5M / Series A / Sep 27, 2021 | |
|
Virasoft
|
ViraSoft’s ambition is to be the first choice in the field of digital pathology in Turkey and in mid-term enabling to give service to the neighboring countries. Together with the R&D activities, we aim to improve the efficiency and effectivity in the pathology process and reach significant diagnosis results. | $2.5M / Seed / Sep 27, 2021 | |
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Eczacıbaşı Momentum invest in?
Eczacıbaşı Momentum invests primarily in E-Commerce, Information Technology and FinTech startups, most often at Seed and Series A stage. Most of the 15 investments tracked by Shizune back companies in Turkey. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Eczacıbaşı Momentum's check size?
Eczacıbaşı Momentum typically joins rounds of $125k–$9M at Seed, $125k–$125k at Pre-Seed and $2.5M–$65M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Eczacıbaşı Momentum participates in.
How do I contact Eczacıbaşı Momentum?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Eczacıbaşı Momentum?
The team at Eczacıbaşı Momentum includes Berktug Incekas (Head of VC Investments) and Çağdaş Aygün (VC Investments). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
